Antitumor activity, distribution, and metabolism, of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 3, 1999, Pages 183-197

  Conley, Barbara A ^a,b   Ramsland, Thomas S ^a   Sentz, Dorothy L ^a   Wu, Suhlan ^a   Rosen, D Marc ^a   Wollman, Megan ^a   Eiseman, Julie L ^a,b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

13 cis Retinoic acid; Breast cancer; MCF 7 xenografts; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; ISOTRETINOIN; RETINOIC ACID; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG MIXTURE; FEEDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; ISOTRETINOIN; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032922252     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050883     Document Type: Article

References (31)

1. Adamson PC, Pitot HC, Balis FM, Rubin J, Murphy RF, Poplack DG (1993) Variability in the oral bioavailability of all trans retinoic acid. J Natl Cancer Inst 85: 993
2. Alfthan O, Tarkkanen J, Grohn P, Heinonen F, Pyronen S, Saila K (1983) Tigason (etretinate) in the prevention of recurrence of superficial bladder tumors. Eur Urol 9: 6
3. Astrom A, Pettersson U, Krust A, Chambon P, Voorhees JJ (1990) Retinoic acid and synthetic analogs differentially activate retinoic acid receptor dependent transcription. Biochem Biophys Res Comm 173: 339
4. Bugge CJL, Rodriquez LC, Vane FM (1985) Determination of isotretinoin or etretinate and their major metabolites in human blood by reversed-phase high performance liquid chromatography. J Pharm Biomed Anal 3: 269
5. Cassidy J, Lippman M, Lacroix A, Peck G (1982) Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. Eur J Cancer Clin Oncol 18: 925
6. Castaigne C, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L (1990) All trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76: 1704
7. Conley BA, Egorin MJ, Sridhara R, Finley R, Hemady R, Wu S, Tait N, Van Echo DA (1997) Phase I clinical trial of all-trans retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol 39: 291
8. D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Methods Prog Biomed 9: 115
9. Degos L, Chomienne C, Daniel MT, Berger R, Dombret H, Fenaux P, Castaigne S (1990) Treatment of first relapse in acute promyclocytic leukemia with all trans retinoic acid. Lancet 336: 1440
10. Fontana J (1987) Interaction of retinoids and tamoxifen on inhibition of human mammary carcinoma cell proliferation. Exp Cell Biol 55: 136
11. Halter SA, Fraker LD, Adcock D, Vick S (1988) Effect of retinoids on xenotransplanted human mammary carcinoma cells in athymic mice. Cancer Res 48: 3733
12. Hill DL, Struck RF (1983) Pharmacologic disposition of chemopreventive retinoids. Anticancer Res 3: 171
13. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fotonoff S, Byers R, Atkinson EN, Vaughan C, Toth BB, Kramer A, Dimery IW, Skipper P, Strong S (1986) 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315: 1501
14. Huang M, Ye Y, Chen S, Chai J, Lu J-X, Zhoa L, Gu L, Wang Z (1988) Use of all-transretinoic acid in the treatment of acute leukemia. Blood 72: 567
15. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13: 513
16. AA as catalyst of 4-hydroxylation induced by TCDD and betaNF. Cancer Res 54: 3140
17. Lotan R, Nicholson GL (1977) Inhibitory effects of retinoic acid or retinyl acetate on the growth of untransformed, transformed, and tumor cells in vitro. J Natl Cancer Inst 59: 1717
18. McCormick DL, Moon RC (1986) Retinoid-tamoxifen interaction in mammary cancer chemoprevention. Carcinogenesis (London) 7: 193
19. McCormick DL, Sowell ZL, Thompson CA, Moon RC (1983) Inhibition by retionid and ovariectomy of additional primary malignancies in rats following surgical removal of the first mammary cancer. Cancer 51: 594
20. Muindi JR, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW, Warrell RP Jr (1992) Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 52: 2138
21. Rocci ML, Jusko WJ (1983) LAGRAN program for area and moments in pharmacokinetic analysis. Comp Prog Biomed 16: 203
22. Rubin M, Fenig E, Rosenauer A, Menendez-Botet C, Achkar C, Bentel JM, Yahalom J, Mendelsohn J, Miller WH (1994) 9-cis-Retinoic acid inhibits growth of breast cancer cells and down regulates estrogen receptor RNA and protein. Cancer Res 54: 6549
23. Shah JP, Strong EW, DeCrossee JJ, Itri L, Sellers P (1983) Effects of retinoids on oral leukoplakia. Am J Surg 146: 466
24. Sheikh MS, Shao ZM, Li XS, Dawson M, Jetten AM, Wu S, Conley BA, Garcia M, Rochefort H, Fontana JA (1994) Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor alpha acquire sensitivity to growth inhibition by retinoids. J Biol Chem 269: 21440
25. Sheikh MS, Shao ZM, Li X-S, Ordonez JV, Conely BA, Wu S, Dawson ML, Han QX, Chao WR, Quick T, Niles RM, Fontana JA (1995) N-(4-Hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 16: 2477
26. Smith MA, Parkinson DR, Cheson BD, Friedman MA (1992) Retinoids in cancer therapy. J Clin Oncol 10: 839
27. Studer UE, Bidermann C, Chollet D, Jenzer S, Kraft R, Thomamichel G, Vonvanck F, Wuscher V (1986) Reduction of superficial bladder tumor recurrencies by etretinate. J Urol 135: 283A
28. Toma S, Isnardi L, Raffo P, Dastoli G, DeFrancisci E, Riccardi L, Palumbo R, Bollag W (1997) Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction. Int J Cancer 70: 619
29. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon M, Dmitrovsky E (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 324: 1385
30. Wetherell NT, Taylor CM (1986) The effects of retinoid treatment and antiestrogens on the growth of T47D human breast cancer cells. Eur J Cancer Clin Oncol 22: 53
31. Yeh KC, Kwan KC (1978) A comparison of numerical integrating algorithms by trapezoidal, LaGrange and Spline approximation. J Pharmacokinet Biopharm 6: 79